bronchiectasis
Jump to navigation
Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29]
Introduction
Chronic dilation of bronchi or bronchioles as a sequel of inflammatory disease or obstruction.
Etiology
- infection
- pneumonia (reversible cause)
- COPD, chronic bronchitis (reversible cause)
- organisms
- bacterial
- tuberculosis (especially affecting upper lobes)
- Mycobacterium avium complex[12][13]
- pertussis as child may lead to bronchiectasis as adult[5]
- viral
- adenovirus in adults
- measles or influenza in children
- HIV1 infection
- fungal (chronic mycoses) (affects upper lobes)
- *histoplasmosis (not typical)[12]
- coccidioidomycosis
- allergic bronchopulmonary aspergillosis
- bacterial
- acute exacerbation
- ciliary dyskinesia (immotile cilia syndrome)
- inherited
- acquired (especially smoking)
- immunoglobulin disorders
- HIV1 infection
- right middle lobe syndrome (Mycobacterium avium complex)
- allergic bronchopulmonary aspergillosis (asthma, eosinophilia, high serum IgE)
- affects upper lobes
- reversible cause
- yellow nail syndrome
- congenital
- Young's syndrome
- Mounier-Kuhn syndrome
- unilateral hyperlucent lung syndrome
- cystic fibrosis (affects upper lobes)
- uncommon causes
- alpha-1 antitrypsin deficiency
- connective tissue diseases
- rheumatoid arthritis (Felty's syndrome)
- scleroderma
- Sjogren's syndrome
- systemic lupus erythematosus
- toxic inhalation
- chronic tracheobronchial stenosis
- recurrent pulmonary aspiration
- heroin
- inflammatory bowel disease
- ulcerative colitis, Crohn's disease
- foreign body - asbestosis
- sequestrated lung
- chronic tracheoesophageal fistula
- heart-lung transplantation
- lung transplantation rejection
- chronic granulomatous disease
- chronic hypersensitivity pneumonitis
- radiation therapy
- sarcoidosis
- asthma
- Marfan syndrome
- lymphadenpathy[5]
- neoplasms
Epidemiology
- occurs in both smokers & non-smokers[5]
- non cystic fibrosis patients
- 79% women, 75% diagnosed age 50-75 years[10]
Pathology
- most commonly occurs in lower lung fields
- in most cases 2nd to 4th order bronchi are involved
- bilateral involvement in 30%
- ~20% of patients with bronchiectasis have eosinophilic inflammation[20]
Clinical manifestations
- chronic productive cough
- sputum
- frequently purulent, but not necessariy
- frequently copious
- may be foul smelling (fetor oris)
- may be occasionally blood-tinged
- recurrent bronchial infection, pneumonia
- transient improvement with antibiotics
- sinusitis may be present
- hemoptysis may occur (especially in areas of old tuberculosis)
- coarse rales at lung bases
- clubbing of fingers
- arthralgia
- hypertrophic pulmonary osteoarthropathy
- anorexia & weight loss
- dyspnea common
- wheezing lower lobe (case report, MKSAP20)[5]
- scattered inspiratory crackles (case report, MKSAP20)[5]
- fatigue common
Laboratory
- sputum cultures yield a mixture of organisms
- sputum forms layers on standing
- serum IgA, serum IgG, serum IgM
- complete blood count
- eosinophil count (> 300/uL eosinophilic bronchiectasis)*
- antibodies to Aspergillus[11]
* eosinophil count < 100/uL associated with greater disease severity & mortality[20]
* higher eosinophilic counts were associated with shorter time to exacerbations[20]
Diagnostic procedures
- angiography by interventional radiology for massive hemoptysis
- pulmonary function testing:
- generally shows obstructive lung disease (50%)
- 20% with restrictive pattern[10]
- flexible bronchoscopy with bronchoalveolar lavage
- identify obstruction
- testing for infections missed by sputum culture[5]
- skin testing for Aspergillus fumigatus (immediate cutaneous reactivity)
Radiology
- chest X-ray
- may appear normal even with advanced disease
- patches of increased density at lung bases
- crowding of bronchi
- segmental atelectasis
- honeycombing with cystic spaces measuring < 2.0 cm
- loss of lung volume
- air-fluid level (if cystic bronchiectasis is present)
- 'tram lines' from inciting event, i.e. pneumonia in childhood
- nodular opacities in right middle lobe
- high-resolution computed tomography (CT) of thorax has replaced bronchography as the diagnostic modality of choice
- signet-ring shadows
- dilated bronchus (ring) with bronchial artery (stone)
- bronchial wall thickening
- dilated bronchi extending to the periphery
- airway larger than accompanying blood vessel
- lack of distal airway tapering
- bronchial obstruction secondary to inspissated purulent secretions
- loss of lung volume
- air-fluid level (if cystic bronchiectasis is present)
- signet-ring shadows
Complications
- severe hemoptysis
- progressive respiratory failure with hypoxemia
- cor pulmonale
- secondary infection
- generally saprophytic infection with fungi &/or mycobacteria
- Pseudomonas aeruginosa
- most commonly isolated organism
- impossible to erradicate
- infection with Pseudomonas correlates with more extensive disease
Differential diagnosis
- pulmomary emphysema (COPD)
- multiple sharply defined areas of low attenuation are characteristic of centrilobular emphysema[5]
- paraseptal emphysema & bullae also in subpleural lung regions[5]
- obstructive lung disease on spirometry
- bullous lung disease
Management
- determine if underlying treatable cause(s)
- treat underlying disorders aggressively
- treatment aimed at controlling symptoms, clearing airway, treating infection & preventing exacerbations[5]
- postural drainage
- chest physiotherapy
- humidification
- acute exacerbations
- respiratory fluoroquinolone (levofloxacin, moxifloxacin) to ensure coverage for Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, & Pseudomonas aeruginosa for 10-14 days[5][11]
- ciprofloxacin may also be used[5]
- despite its non-respiratory fluoroquinolone status[5]
- best activity among fluoroquinolones against Pseudomonas aeruginosa
- use of glucocorticoids not recommended in the absence of asthma or allergic bronchopulmomary aspergillosis
- in hospital-acquired pneumonia &/or recent antibiotic use (within 90 days) coverage for multi-drug-resistant Pseudomonas & MRSA
- vancomycin + cefepime, Zosyn or meropenem + fluroquinolone
- vancomycin + aztreonam or meropenem + fluroquinolone if penicillin allergy[23]
- cyclic antibiotic therapy
- daily azithromycin 250 mg results in fewer exacerbations at a cost of antibiotic resistance[6]
- macrolide maintenance therapy may be associated with fewer cardiovascular events[24]
- brensocatib reduces activity of neutrophil proteases that contribute to airway inflammation[26] (not yet FDA-approved)
- no benefit for routine use of bronchodilators[5]
- no benefit for hypertonic saline nebulizer as an expectorant, or oral carbocisteine to regulate mucous secretion[29]
- no benefit of long-term systemic glucocorticoids[5]
- patients with blood eosinophils > 400/uL may benefit from inhaled glucocorticoids[28]
- pulmonary rehabilitation[5]
- improves exercise capacity
- reduces emergency department & outpatient visits
- surgery
- lack of evidence-based interventions[10]
- no role for statins[11]
More general terms
More specific terms
Additional terms
- allergic bronchopulmonary aspergillosis; allergic bronchopulmonary mycosis (ABPA)
- Bruton type agammaglobulinemia
- ciliary dyskinesia; immotile cilia syndrome (Kartagener's syndrome)
- hyperimmunoglobulin E (Job's syndrome)
- right middle lobe syndrome
- selective IgA deficiency
- yellow nail syndrome (lymphedema & yellow nails)
- Young's syndrome (obstructive azoospermia)
References
- ↑ Stedman's Medical Dictionary 26th ed, Williams & Wilkins, Baltimore, 1995
- ↑ Guide to Physical Examination & History Taking, 4th edition, Bates B, JB Lippincott, Philadelphia, 1987
- ↑ DeGowin & DeGowin's Diagnostic Examination, 6th edition, RL DeGowin (ed), McGraw Hill, NY 1994, pg 870
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 746-48
- ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 5.14 5.15 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2006, 2015, 2018, 2022.
Medical Knowledge Self Assessment Program (MKSAP) 20 American College of Physicians, Philadelphia 2025 - ↑ 6.0 6.1 Altenburg J et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. JAMA 2013 Mar 27; 309:1251 PMID: https://pubmed.ncbi.nlm.nih.gov/23532241
Serisier DJ et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA 2013 Mar 27; 309:1260 PMID: https://pubmed.ncbi.nlm.nih.gov/23532242 - ↑ Chalmers JD, Smith MP, McHugh BJ et al Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012 Oct 1;186(7):657-65. PMID: https://pubmed.ncbi.nlm.nih.gov/22744718
- ↑ McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013 Sep 15;188(6):647-56 PMID: https://pubmed.ncbi.nlm.nih.gov/23898922
- ↑ Pasteur MC, Bilton D, Hill AT et al British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010 Jul;65 Suppl 1:i1-58. Review. PMID: https://pubmed.ncbi.nlm.nih.gov/20627931
- ↑ 10.0 10.1 10.2 10.3 10.4 10.5 Aksamit TR et al. Adult patients with bronchiectasis: A first look at the US Bronchiectasis Research Registry. Chest 2017 May; 151:982 PMID: https://pubmed.ncbi.nlm.nih.gov/27889361
- ↑ 11.0 11.1 11.2 11.3 Anello J, Feinberg B, Heinegg J et. al. New Guidelines and Recommendations, October 2017 Medscape. Oct 06, 2017. http://reference.medscape.com/viewarticle/886616_15
- ↑ 12.0 12.1 12.2 NEJM JWatch Question of the Week. March 27, 2018 https://knowledgeplus.nejm.org/question-of-week/562/
- ↑ 13.0 13.1 Ebihara T, Sasaki H. Bronchiectasis with Mycobacterium avium Complex Infection. N Engl J Med 2002; 346:1372 <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/11986411 Free full text <Internet> http://www.nejm.org/doi/full/10.1056/NEJMicm010899
- ↑ 14.0 14.1 NEJM Knowledge+ Question of the Week. June 19, 2018 https://knowledgeplus.nejm.org/question-of-week/1699/
- ↑ Milliron B, Henry TS, Veeraraghavan S, Little BP. Bronchiectasis: Mechanisms and Imaging Clues of Associated Common and Uncommon Diseases. Radiographics. 2015 Jul-Aug;35(4):1011-30. Review. PMID: https://pubmed.ncbi.nlm.nih.gov/26024063
- ↑ Smith MP. Diagnosis and management of bronchiectasis. CMAJ. 2017 Jun 19;189(24):E828-E835. Review. PMID: https://pubmed.ncbi.nlm.nih.gov/28630359 Free PMC Article
- ↑ NEJM Knowledge+ Question of the Week. April 16, 2019 https://knowledgeplus.nejm.org/question-of-week/561/
- ↑ Barker AF. Bronchiectasis. N Engl J Med 2002 May 3; 346:1383. PMID: https://pubmed.ncbi.nlm.nih.gov/11986413 https://www.nejm.org/doi/full/10.1056/NEJMra012519
- ↑ Feldman C. Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med. 2011 Sep;32(3):535-46. Review. PMID:21867821
- ↑ 20.0 20.1 20.2 20.3 Shoemark A et al. Characterization of eosinophilic bronchiectasis: A European multicohort study. Am J Respir Crit Care Med 2022 Apr 15; 205:894. PMID: https://pubmed.ncbi.nlm.nih.gov/35050830 https://www.atsjournals.org/doi/10.1164/rccm.202108-1889OC
Singh D, Brightling C. Bronchiectasis, the latest eosinophilic airway disease: What about the microbiome? Am J Respir Crit Care Med 2022 Apr 15; 205:860. PMID: https://pubmed.ncbi.nlm.nih.gov/35213295 https://www.atsjournals.org/doi/10.1164/rccm.202201-0105ED - ↑ NEJM Knowledge+ Question of the Week. Nov 8, 2022 https://knowledgeplus.nejm.org/question-of-week/233/
Thompson GR, Young JAH. Aspergillus infections. PMID: https://pubmed.ncbi.nlm.nih.gov/34644473 N Engl J Med 2021; 385:1496-1509 https://www.nejm.org/doi/full/10.1056/NEJMra2027424
Patel G, Greenberger PA. Allergic bronchopulmonary aspergillosis. Allergy Asthma Proc 2019 Nov 1; 40:421-424. PMID: https://pubmed.ncbi.nlm.nih.gov/31690385
Shah A, Panjabi C. Allergic bronchopulmonary aspergillosis: a perplexing clinical entity. Allergy Asthma Immunol Res 2016 Jul; 8:282-97. PMID: https://pubmed.ncbi.nlm.nih.gov/27126721 PMCID: PMC4853505 Free PMC article - ↑ O'Donnell AE. Bronchiectasis. Chest. 2008 Oct;134(4):815-823. PMID: https://pubmed.ncbi.nlm.nih.gov/18842914 Review.
- ↑ 23.0 23.1 NEJM Knowledge+
- ↑ 24.0 24.1 Guo R et al. Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis. Eur Respir J 2025 Mar; 65:2401574 PMID: https://pubmed.ncbi.nlm.nih.gov/39603670 PMCID: PMC11883147 https://publications.ersnet.org/content/erj/65/3/2401574
- ↑ Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res. 2018;5:e000348. PMID: https://pubmed.ncbi.nlm.nih.gov/30687502
- ↑ 26.0 26.1 Chalmers JD et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 2025 Apr 24; 392:1569 PMID: https://pubmed.ncbi.nlm.nih.gov/40267423 https://www.nejm.org/doi/10.1056/NEJMoa2411664
Bell SC, Grimwood K. Brensocatib in bronchiectasis - A new sheriff in town? N Engl J Med 2025 Apr 24; 392:1647. PMID: https://pubmed.ncbi.nlm.nih.gov/40267431 https://www.nejm.org/doi/10.1056/NEJMe2502618 - ↑ Aliberti S, Goeminne PC, O'Donnell AE, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. 2022;10:298-306. PMID: https://pubmed.ncbi.nlm.nih.gov/34570994
- ↑ 28.0 28.1 Pollock J et al. Use of inhaled corticosteroids in bronchiectasis: Data from the European Bronchiectasis Registry (EMBARC). Thorax 2025 Jun; 80:358. PMID: https://pubmed.ncbi.nlm.nih.gov/40122611 PMCID: PMC12128780 https://pmc.ncbi.nlm.nih.gov/articles/PMC12128780/
- ↑ 29.0 29.1 Bradley JM et al. Hypertonic saline or carbocisteine in bronchiectasis. N Engl J Med 2025 Oct 23; 393:1565. PMID: https://pubmed.ncbi.nlm.nih.gov/41020514 https://www.nejm.org/doi/10.1056/NEJMoa2510095
Hansen-Flaschen J, Tino G. Time to reconsider mucoactive agents for airway clearance. N Engl J Med 2025 Oct 23; 393:1646. PMID: https://pubmed.ncbi.nlm.nih.gov/41020522 https://www.nejm.org/doi/10.1056/NEJMe2512146